Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients. (Q47230237)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23754673%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23754673%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23754673%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Natalino Simioni

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23754673%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Vera Frison

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23754673%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Michela Dal Pos

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23754673%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Michela Bettio

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23754673%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Paola Rocchini

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23754673%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Angelo Avogaro

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23754673%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

11 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23754673%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23754673%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23754673%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23754673%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

943-949

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23754673%20AND%20SRC:MED&resulttype=core&format=json

Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.

2 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0489-3

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0489-3

The metabolic syndrome influences the response to incretin-based therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0489-3

The biology of incretin hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0489-3

Liraglutide: short-lived effect on gastric emptying -- long lasting effects on body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0489-3

Gastrointestinal hormone actions in the central regulation of energy metabolism: potential sensory roles for the circumventricular organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0489-3

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0489-3

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0489-3

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0489-3

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0489-3

Weight-independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0489-3

Effects of sleeve gastrectomy and medical treatment for obesity on glucagon-like peptide 1 levels and glucose homeostasis in non-diabetic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0489-3

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0489-3